Showing 41 - 60 results of 40,686 for search '(((( ((a large) OR (b large)) decrease ) OR ( b largest decrease ))) OR ( i large increased ))*', query time: 1.59s Refine Results
  1. 41
  2. 42
  3. 43

    Table 1_Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.docx by Dewan Zhao (21547445)

    Published 2025
    “…High baseline high-density lipoprotein cholesterol (HDL-C) was associated with reduced progression risk (HR = 0.27, 95% CI: 0.10-0.78), while high baseline low-density lipoprotein cholesterol (LDL-C) was linked to decreased CR rate (OR = 0.65, 95% CI: 0.44-0.97) and increased progression risk (HR = 1.78, 95% CI: 1.14-2.79). …”
  4. 44
  5. 45
  6. 46
  7. 47
  8. 48

    Table_2_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  9. 49

    Table_1_Tumor Immune Microenvironment Components and Checkpoint Molecules in Anaplastic Variant of Diffuse Large B-Cell Lymphoma.pdf by Tianqi Xu (9574329)

    Published 2021
    “…Background<p>Anaplastic diffuse large B-cell lymphoma(A-DLBCL) is a rare morphological subtype characterized by the presence of polygonal, bizarre-shaped tumor cells. …”
  10. 50
  11. 51
  12. 52

    Supplementary Material for: High-sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care by Esau D. (20563829)

    Published 2025
    “…Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. …”
  13. 53
  14. 54
  15. 55

    Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  16. 56
  17. 57
  18. 58

    Image_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.TIFF by Zhixing Kuang (10809975)

    Published 2021
    “…Cachexia-inducing factors (CIFs) have been reported in colorectal cancer and pancreatic adenocarcinoma, but their value in diffuse large B-cell lymphoma (DLBCL) requires further genetic research.…”
  19. 59

    Table_1_Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.xls by Zhixing Kuang (10809975)

    Published 2021
    “…Cachexia-inducing factors (CIFs) have been reported in colorectal cancer and pancreatic adenocarcinoma, but their value in diffuse large B-cell lymphoma (DLBCL) requires further genetic research.…”
  20. 60

    Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”